Patterns and Costs of Antipsychotic Drug Use in Taiwan: 1997 to 2001

Advances in Therapy

Volumn 20, Issue 6, 2003, Pages 344-351

  Chou, Li Fang ^a  

^a NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Cost analysis; Drug utilization; Pharmacoeconomics; Prescribing

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; DIAZEPINE DERIVATIVE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; FLUPHENAZINE; INDOLE DERIVATIVE; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPINE DERIVATIVE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROCHLORPERAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; THIAZEPINE DERIVATIVE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ARTICLE; COST BENEFIT ANALYSIS; DATA BASE; DISEASE CLASSIFICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG UTILIZATION; HUMAN; MENTAL DISEASE; MOOD DISORDER; NATIONAL HEALTH INSURANCE; PRESCRIPTION; PREVALENCE; REIMBURSEMENT; SCHIZOPHRENIA; TAIWAN;

EID: 1542618574     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849801     Document Type: Article

References (14)

1. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr Res. 2001;47:281-292.
2. Leslie DL, Rosenheck R. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia. J Nerv Ment Dis. 2001;189:377-383.
3. Dewa CS, Goering P. Lessons learned from trends in psychotic drug expenditures in a Canadian province. Psychiatr Serv. 2001;52:1245-1247.
4. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002;53:425-430.
5. Daumit GL, Crum RM, Guallar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003;60:121-128.
6. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry. 2003;37:55-61.
7. Bureau of National Health Insurance. 2001 National Health Insurance Annual Statistical Report. Taipei, Taiwan: Bureau of National Health Insurance; 2002.
8. Su TP, Chen TJ, Hwang SJ, Chou LF, Fan AP, Chen YC. Utilization of psychotropic drugs in Taiwan: an overview of outpatient sector in 2000. Zhonghua Yi Xue Za Zhi (Taipei). 2002;65:378-391.
9. Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1997-2000. Int J Clin Pharmacol Ther. 2003;41:207-212.
10. Chen TJ, Chou LF, Hwang SJ. Prevalence of anti-ulcer drug use in a Chinese cohort. World J Gastroenterol. 2003;9:1365-1369.
11. Chen TJ, Chou LF, Hwang SJ. Utilization of hepatoprotectants within the National Health Insurance in Taiwan. J Gastroenterol Hepatol. 2003;18:868-872.
12. Chen TJ, Chou LF, Hwang SJ. Application of a data-mining technique to analyze coprescription patterns for antacids in Taiwan. Clin Ther. 2003;25:2453-2463.
13. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment, 3rd ed. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2000.
14. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Invest. 2003;23:287-322.